Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Comparison of the EyeCee One with the Acrysof SN60WF hydrophobic acrylic intraocular lens: 3 year-results of a randomized trial

Poster Details

First Author: C.Leydolt AUSTRIA

Co Author(s):    S. Schriefl   D. Schartmueller   R. Menapace              

Abstract Details

Purpose:

The aim of this study was to compare the capsular performance and intensity of posterior capsule opacification (PCO) of the EyeCee One intraocular lens (IOL) (Nidek Co., Aichi, Japan) with the Acrysof SN60WF IOL (Alcon, Fort Worth, Texas).

Setting:

Department of Ophthalmology, Medical University Vienna, Austria

Methods:

This prospective,randomized study comprised 160 eyes of 80 patients. Each patient randomly received an EyeCee One IOL in one eye and an Acrysof SN60WF IOL in the contralateral eye. Follow-up examinations were performed six months, 1.5 years and three years after surgery. Capsular bag performance (slitlamp examination, IOL decentration and tilt, fibrosis), the appearance of glistenings, as well as the amount of PCO (objectively evaluated via digital retroillumination images and Automated Quantification of After-Cataract [AQUA]) were assessed.

Results:

Both IOLs show comparable results regarding IOL decentration and tilt, fibrosis and slitlamp examination sic months and 1.5 years postoperatively. There was no significant difference in objective PCO score for both IOLs (p = 0.06). The Acrysof SN60WF IOL showed significant more glistenings than the EyeCee One IOL (p < 0.05). Results three years postoperatively will be presented.

Conclusions:

Both hydrophobic acrylic IOLs show good capsular bag performance and low PCO rates.

Financial Disclosure:

NONE

Back to Poster listing